SAN DIEGO, June 25 /PRNewswire/ --
Introgen Therapeutics, Inc. (Nasdaq: INGN), a leading developer of gene based
therapeutics for cancer and other diseases today announced that Dr. James
Merritt, vice president for clinical affairs of Introgen, is scheduled to
update investors this week by giving a corporate overview of Introgen's
programs at the annual meeting of the Biotechnology Industry Organization
(BIO) during the International Investor and Partnering Forum in San Diego,
California.
The presentation will take place on Tuesday, June 26, 2001 at 4:00 p.m. PT
at the San Diego Convention Center, Sails Pavilion. The presentation will be
broadcast live via the Internet and can be accessed at
http://www.informedinvestors.com/iif_forums/client_capsule.cfm?companyID=845.
Following the live presentation, the Web cast will be archived for 30 days
and can be accessed at the above referenced address.
Introgen is a leader in the development and production of gene-based drugs
for the treatment of cancer and other diseases. Introgen's product candidates
engage precise molecular targets to produce a highly specific therapeutic
effect. Introgen specializes in combining appropriate gene delivery systems
and therapeutic genes to make its gene-based drugs. Introgen's lead product
candidate, INGN 201, is currently in Phase III clinical trials for the
treatment of head and neck cancer. INGN 201 has been used in numerous
clinical trials worldwide either alone or in combination with conventional
treatments such as chemotherapy and radiotherapy. Introgen is also conducting
a Phase II clinical trial for INGN 201 in lung cancer and Phase I trials for
INGN 201 in additional cancer indications including prostate, ovarian,
bladder, brain, and breast cancer. In an announcement earlier this year,
Introgen published results of preclinical studies which indicate a possible
application of INGN 201 whereby the human immune system may be directed to
attack tumor cells. Introgen's second product candidate, INGN 241
(Adenoviral-mda7), for the treatment of solid tumors, is in Phase I clinical
development. Introgen controls a broad intellectual property portfolio that
includes more than 200 pending and issued patents for a variety of gene
therapy technologies. Introgen owns a fully staffed and validated Good
Manufacturing Practices (cGMP) production facility that is producing Phase III
and commercial inventory of INGN 201. Introgen has received a U.S. patent for
the commercial scale production of adenovirus.
Certain statements in this press release that are not strictly historical
may be "forward-looking" statements, which involve risks and uncertainties.
Such forward-looking statements include, but are not limited to, those
relating to safety and efficacy of drug product candidates and Introgen's
ability to complete its clinical trials, or successfully commercialize any
product candidates. There can be no assurance that Introgen will be able to
commercially develop gene-based drugs, that necessary regulatory approvals
will be obtained or that any clinical trials or studies undertaken will be
successful or that the proposed treatments will prove to be safe and/or
effective. The actual results may differ from those described in this press
release due to risks and uncertainties that exist in Introgen's operations and
business environment, including, but without limitation, Introgen's stage of
product development and the limited experience in the development of gene-
based drugs in general, its dependence upon proprietary technology and current
competition, history of operating losses and accumulated deficits, Introgen's
reliance on collaborative relationships, and uncertainties related to clinical
trials, safety, efficacy, the ability to obtain the appropriate regulatory
approvals, patent protection and market acceptance, as well as other risks
detailed from time to time in Introgen's filings with the Securities and
Exchange Commission, including its prospectus dated October 12, 2000 and the
10-Q filed on May 14, 2001. Introgen undertakes no obligation to publicly
release the results of any revisions to any forward-looking statements that
reflect events or circumstances arising from the date hereof.
Editor's Note: For more information on Introgen Therapeutics, or for a
menu of archived press releases, please visit the Company Website at:
http://www.introgen.com, or call Introgen's toll-free Investor Relations hotline at
1-877-776-GENE (4363).
Contact:
Introgen Therapeutics, Inc.
C. Channing Burke
(512) 708 9310 Ext. 322
Email: c.burke@introgen.com
Noonan/Russo Communications
Matthew J. Scampoli
(212) 696 4455 Ext. 243
Email: m.scampoli@noonanrusso.com
SOURCE Introgen Therapeutics, Inc.
 back to top
Related links:
http://www.bio.org
http://www.introgen.com
http://www.informedinvestors.com/iif_forums/client_capsule.cfm?companyID=845
CONTACT:
C. Channing Burke of Introgen Therapeutics,
Inc., 512-708-9310, ext. 322, or c.burke@introgen.com; or Matthew
J. Scampoli of Noonan/Russo Communications, 212-696-4455, ext.
243, or m.scampoli@noonanrusso.com, for Introgen Therapeutics,
Inc.
|
